SCGB1A1 and chronic obstructive pulmonary disease: Previous studies have shown that recombinant CC16 can help to decrease airway inflammatory response in chronic obstructive pulmonary disease (COPD) and acute respiratory disease syndrome (ARDS) (Pang et al. 2018; Lopez et al. 2020).